Lasker Officials Vow To Carry On In Tradition Established By Alice Fordyce

There won't be any loss of continuity in the Albert Lasker Medical Research Awards program caused by the recent death of Alice Fordyce, former executive vice president of the New York- based Albert and Mary Lasker Foundation, say scientists associated with the program. Fordyce died September 9 at the age of 86, after a brief illness. Jordan U. Gutterman, who replaced Fordyce as Lasker Foundation executive vice president and director of the Lasker awards program on Dec. 31, 1990, says that the

Written byBarbara Spector
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Jordan U. Gutterman, who replaced Fordyce as Lasker Foundation executive vice president and director of the Lasker awards program on Dec. 31, 1990, says that the time he spent discussing the program with Fordyce before her death provided the necessary background he needed to ensure its successful continuation. Says Gutterman, who administered the awards for the first time when they were given in 1991, after a one-year moratorium in 1990: "Although she traveled a lot that year, she was available quite a bit for me."

Gutterman says that, since "we were already going through a transition because she had stepped down," there should be minimal disruption due to the loss of Fordyce. "It was good we had experience without her directly involved," says Gutterman, who is chairman of the department of clinical immunology and biological therapy at the University of Texas M.D. Anderson Cancer Center in Houston.

Fordyce, together with ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies